Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Years of opioid use do not improve chronic back pain, study finds (opens in a new tab)

medicalxpress.com · 2026-10-07

Short answerEvidenceSource

Short answer

Mostly not supported

Mostly not supported.

2 claims go further than the study. 3 other points were not covered by the paper.

  • 1 supported
  • 2 overstated
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly not supported

Two of six claims overstate the study. One of six checks out. Three claims the study doesn't address.

  • 1 supported
  • 2 overstated
  • 3 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

6 claims in this story

Showing all 6 claimsChoose a verdict to focus the list.

Claim 1 of 6OverstatedTaking opioids for years does not seem to reduce pain or improve functioning in people with chronic back pain, according to a new Northwestern University study that compared 70 long-term opioid users with 70 similar patients not taking opioids.View evidenceHide evidence

As stated70 long-term opioid users and 70 similar nonusers

Why this verdict

The paper profile supports an observational comparison of 70 long-term prescribed opioid users with 70 tightly matched opioid-naïve chronic back pain patients, with mean opioid exposure of 7.8 years and only modestly worse psychosocial profiles in the opioid group. But the story frames this as evidence that opioids did not reduce pain or improve functioning over years, which is an efficacy/causal-strength interpretation not established by the cross-sectional case-control design. The headline-prominence wording outruns the paper’s observational evidence and the story’s own caveats.

1

Study evidence

CBP+O patients showed only modestly worse psychosocial profiles compared with matched opioid-naïve CBP patients.

“we contrasted the psychosocial profiles and brain structure and function of 70 chronic back pain patients prescribed opioids (CBP+O, average current daily opioid exposure of 7.8 years) with tightly matched 70 opioid-naïve patients (CBP-O) and 30 healthy subjects.”
2

Study evidence

Psychosocial questionnaire data across 140 CBP patients were reduced to three principal components (functional disability, pain quality, negative affect) that together explained 70% of variance.70% variance explained

“The patients' (across all 140 CBP) psychosocial profiles were summarized by three principal components (PCs, explaining 70% of variance): functional disability, pain quality, and negative affect.”
Claim 2 of 6OverstatedThe study also found large differences in brain activity between the two groups and identified new molecular markers, including some involving serotonin receptors, that could lead to new treatments for pain and for tapering off opioids.View evidenceHide evidence

Why this verdict

The abstract-level profile supports stark ALFF brain-activity differences and receptor-linked associations involving serotonergic receptors and MOR. It also supports additional associations with tapering success and pain intensity. However, saying the study identified molecular markers that could lead to new treatments for pain and tapering off opioids goes beyond the supplied paper profile, which reports associative molecularly informed brain-circuit findings rather than treatment development evidence.

1

Study evidence

CBP+O patients showed only modestly worse psychosocial profiles compared with matched opioid-naïve CBP patients.

“we contrasted the psychosocial profiles and brain structure and function of 70 chronic back pain patients prescribed opioids (CBP+O, average current daily opioid exposure of 7.8 years) with tightly matched 70 opioid-naïve patients (CBP-O) and 30 healthy subjects.”
2

Study evidence

A multivariate model using 19 receptor/transporter distributions captured a large portion of the ALFF group-difference pattern.38% variance explained

“A large portion (38% of the variance) of this pattern was captured by a model using 19 receptor/transporter distributions.”
Claim 3 of 6Not coveredBased on these findings, the Northwestern scientists plan to test whether an antidepressant, which targets the same serotonin molecular pathway identified in the study, can help treat chronic pain and opioid dependence.View evidenceHide evidence

Why this verdict

The profile supports serotonergic receptor-linked activity findings and associations with pain intensity, opioid dose, abstinence status, and tapering success. But the abstract-level paper profile does not mention a planned antidepressant trial, the specific antidepressant, or testing it for chronic pain and opioid dependence. This may be in other article material or full-text discussion, but it is not verifiable from the supplied abstract-depth profile.

1

Study evidence

Psychosocial questionnaire data across 140 CBP patients were reduced to three principal components (functional disability, pain quality, negative affect) that together explained 70% of variance.70% variance explained

“The patients' (across all 140 CBP) psychosocial profiles were summarized by three principal components (PCs, explaining 70% of variance): functional disability, pain quality, and negative affect.”
2

Study evidence

5HT1a- and MOR-related brain activity measures tracked opioid dose, abstinence status, and tapering success in the authors' additional analyses and new data.

“In additional analyses and new data, 5HT1a- and MOR-related activities tracked opioid dose, abstinence status, and tapering success, while 5HT6-related activity tracked pain intensity.”
Claim 4 of 6Not coveredThe opioid group had been taking daily prescription opioids for an average of 7.8 years for chronic back pain, and the two groups reported nearly identical pain scores of about 5.4 out of 10.View evidenceHide evidence

As statedaverage of 7.8 years; pain about 5.4/10

Why this verdict

The mean 7.8 years of daily prescribed opioid exposure is directly supported. However, the abstract-depth profile does not provide the claimed nearly identical pain scores of about 5.4/10 for both groups. Because that numerical pain-score comparison is a material part of the claim, it is not verifiable at the supplied evidence depth.

1

Study evidence

CBP+O patients showed only modestly worse psychosocial profiles compared with matched opioid-naïve CBP patients.

“we contrasted the psychosocial profiles and brain structure and function of 70 chronic back pain patients prescribed opioids (CBP+O, average current daily opioid exposure of 7.8 years) with tightly matched 70 opioid-naïve patients (CBP-O) and 30 healthy subjects.”
Claim 5 of 6Not coveredIn a separate group of 21 patients who completed a four-week pain rehab program, eight reduced opioid use by more than 30%, and their brain activity changed in ways linked to serotonin and opioid receptors.View evidenceHide evidence

As stated21 patients; 8 reduced opioid use by more than 30%

Why this verdict

The abstract-level profile supports that additional analyses/new data found 5HT1a- and MOR-related activities tracked opioid dose, abstinence status, and tapering success. But it does not provide the separate-group size of 21, a four-week pain rehabilitation program, the count of eight patients reducing opioid use by more than 30%, or longitudinal brain-activity changes. Those details are not verifiable from the supplied abstract-depth profile.

1

Study evidence

5HT1a- and MOR-related brain activity measures tracked opioid dose, abstinence status, and tapering success in the authors' additional analyses and new data.

“In additional analyses and new data, 5HT1a- and MOR-related activities tracked opioid dose, abstinence status, and tapering success, while 5HT6-related activity tracked pain intensity.”
Claim 6 of 6SupportedThe article says the researchers built a new computational technique combining MRI data with published brain maps of neurotransmitter receptors and identified molecular signatures associated with chronic pain and long-term opioid use.View evidenceHide evidence

Why this verdict

The profile supports a computational/in-silico analysis combining neuroimaging-derived ALFF patterns with 19 receptor/transporter spatial distribution maps, and it supports receptor-linked molecular signatures involving serotonergic and mu-opioid receptor-related activity. The profile describes these as associative molecularly informed brain-activity signatures related to chronic pain and long-term opioid use.

1

Study evidence

A multivariate model using 19 receptor/transporter distributions captured a large portion of the ALFF group-difference pattern.38% variance explained

“A large portion (38% of the variance) of this pattern was captured by a model using 19 receptor/transporter distributions.”
2

Study evidence

Psychosocial questionnaire data across 140 CBP patients were reduced to three principal components (functional disability, pain quality, negative affect) that together explained 70% of variance.70% variance explained

“The patients' (across all 140 CBP) psychosocial profiles were summarized by three principal components (PCs, explaining 70% of variance): functional disability, pain quality, and negative affect.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Observational case-control design limits causal inference about whether long-term opioids reduce pain or improve functioning.

    The story mentions some context about medically supervised low/moderate doses and relatively intact psychological/brain properties, but it does not clearly state the central interpretation-changing limitation that the study is observational and cannot establish opioid efficacy or lack of efficacy.

    From observational case-control

  • Psychosocial profiles across 140 chronic back pain patients were summarized into three PCs—functional disability, pain quality, and negative affect—explaining 70% of variance and associated with 5HT1a, 5HT6, and MOR-related activity.

    The story mentions serotonin/opioid receptor markers generally, but it does not convey the PCA structure, the three psychosocial dimensions, or the 70% variance explained.

    From human in vivo

  • Receptor/transporter findings are based on atlas-derived spatial maps and receptor-linked activity measures, not direct subject-specific receptor measurements.

    The story’s molecular-marker language could be read as more direct than the supplied profile supports. The profile’s caveat that receptor maps are indirect, population-level atlas-derived measures is not reflected.

    From in_silico multivariate spatial modeling; human in vivo

4 things the story did carry across
  • Primary study compared 70 long-term prescribed opioid users with chronic back pain, 70 matched opioid-naïve chronic back pain patients, and 30 healthy controls.
  • The opioid group showed only modestly worse psychosocial profiles and small morphometric differences, but stark resting-state ALFF brain-activity differences.
  • A model using 19 receptor/transporter distribution maps captured 38% of the ALFF difference pattern.
  • Additional/new-data analyses linked 5HT1a and MOR-related activity with opioid dose, abstinence status, and tapering success, and 5HT6-related activity with pain intensity.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

human in vivo

1Lead resulthuman in vivoContrast psychosocial profiles and brain structure/function between chronic back pain patients with long-term prescribed opioid use (CBP+O) vs matched opioid-naïve chronic back pain patients (CBP-O) and healthy controls.observational case-controlExpand

In plain English

Observational case-control study comparing 70 chronic back pain patients on long-term prescribed daily opioids (CBP+O; mean exposure 7.8 years) with 70 tightly matched opioid-naïve chronic back pain patients (CBP-O) and 30 healthy controls. Outcomes included psychosocial/clinical questionnaires, structural MRI morphometry, and resting-state fMRI amplitude of low-frequency fluctuations (ALFF). Main findings: CBP+O showed only modestly worse psychosocial profiles and small morphometric differences versus CBP-O, but pronounced/stark differences in resting-state brain activity (ALFF). A model based on 19 receptor/transporter distributions captured 38% of the variance in the ALFF pattern. Across the 140 chronic back pain patients, three principal components (functional disability, pain quality, negative affect) explained 70% of the psychosocial variance and were associated with serotonergic (5HT1a, 5HT6) and mu-opioid receptor (MOR)–related activity. Additional analyses (including new data) indicated 5HT1a- and MOR-related activities tracked opioid dose, abstinence status, and tapering success, while 5HT6-related activity tracked pain intensity. Authors conclude these results delineate molecularly defined brain circuit differences related to long-term opioid use and chronic pain.

Key findings

  • CBP+O patients showed only modestly worse psychosocial profiles compared with matched opioid-naïve CBP patients.
  • CBP+O exhibited small differences in brain morphology relative to CBP-O.
“we contrasted the psychosocial profiles and brain structure and function of 70 chronic back pain patients prescribed opioids (CBP+O, average current daily opioid exposure of 7.8 years) with tightly matched 70 opioid-naïve patients (CBP-O) and 30 healthy subjects.”
What this piece can’t prove
  • Observational case-control design: group differences are associative and do not establish causality.
  • Sample sizes limited to 70 CBP+O, 70 CBP-O, and 30 healthy controls; power for some subgroup or secondary analyses may be constrained.

1 further detail could not be confirmed from the summary.

2in silicoExplain variance in altered brain activity (ALFF) using a multivariate model based on receptor/transporter spatial distributions (19 maps), linking molecular systems to functional changes.in silico multivariate spatial modelingExpand

In plain English

An in‑silico multivariate spatial model related the group-difference ALFF brain activity pattern to 19 atlas-derived receptor/transporter distribution maps; the model accounted for 38% of the variance in the ALFF pattern, suggesting that molecular receptor/transporter topographies explain a substantial portion of the observed functional alterations.

Key findings

  • A multivariate model using 19 receptor/transporter distributions captured a large portion of the ALFF group-difference pattern.38% variance explained
“A large portion (38% of the variance) of this pattern was captured by a model using 19 receptor/transporter distributions.”
What this piece can’t prove
  • Use of atlas maps means findings reflect population-average molecular topographies, not individual receptor/transporter variability.

2 further details could not be confirmed from the summary.

3human in vivoDerive latent psychosocial dimensions (PCs) across chronic back pain patients and associate each PC with receptor-linked brain activity patterns (e.g., 5HT1a/5HT6/MOR-related activities).Expand

In plain English

In 140 chronic back pain (CBP) patients (70 opioid-prescribed, 70 opioid-naïve pooled), psychosocial questionnaire data were reduced by principal component analysis to three latent dimensions (functional disability, pain quality, negative affect) that together explained 70% of variance; these three PCs were each associated with distinct receptor-linked brain activity patterns derived from imaging+atlas models, specifically serotonergic markers (5HT1a, 5HT6) and the mu-opioid receptor (MOR).

Key findings

  • Psychosocial questionnaire data across 140 CBP patients were reduced to three principal components (functional disability, pain quality, negative affect) that together explained 70% of variance.70% variance explained
  • Each psychosocial PC was associated with distinct receptor-linked brain activity patterns: associations implicated serotonergic markers (5HT1a, 5HT6) and the mu-opioid receptor (MOR).
“The patients' (across all 140 CBP) psychosocial profiles were summarized by three principal components (PCs, explaining 70% of variance): functional disability, pain quality, and negative affect.”
What this piece can’t prove
  • Abstract does not provide statistical effect sizes, confidence intervals, p-values, or multiple-comparison correction details for the PC-to-receptor associations.

2 further details could not be confirmed from the summary.

4human in vivoValidate/extend receptor-linked activity associations in additional analyses/new data: track opioid dose, abstinence status, tapering success, and pain intensity.additional analyses / new data (validation of receptor-activity associations)Expand

In plain English

The authors report that, in additional analyses and new data, 5HT1a- and mu-opioid receptor (MOR)-related brain activity measures tracked opioid dose, abstinence status, and tapering success, while 5HT6-related activity tracked pain intensity. These analyses are presented as validation/extension of receptor-linked activity associations with clinically relevant opioid-use variables.

Key findings

  • 5HT1a- and MOR-related brain activity measures tracked opioid dose, abstinence status, and tapering success in the authors' additional analyses and new data.
  • 5HT6-related brain activity tracked pain intensity in the additional analyses/new data.
“In additional analyses and new data, 5HT1a- and MOR-related activities tracked opioid dose, abstinence status, and tapering success, while 5HT6-related activity tracked pain intensity.”
What this piece can’t prove
  • The abstract does not clarify whether the 'new data' constitute an independent validation cohort, a longitudinal follow-up, or supplementary analyses of the original sample.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 32 candidate papers

Candidate

ElCon-MN 2026 Author Index

2026 ElCon Conference of Young Researchers in Micro and Nanoelectronics, Electrical Engineering Materials, Plasmas and Fields, Photonics and Electro-Optics (ElCon-MN) · 2026 · Crossref

Source (opens in a new tab)

And 26 more candidates considered.